309:(HIV) and hepatitis C (acquired through transfusion of plasma or plasma-derived factor VIII concentrates) in the 1980s was a devastating blow to the hemophilia community. Lusher therefore participated in several pioneering multi-center studies that tested pasteurized factor concentrates, which eliminated HIV transmission. Lusher also addressed the social stigma associated with the HIV infection, and demonstrated that HIV was not transmitted to the household members of infected patients.
279:, was first discovered in Italy in 1977 by Mannucci and colleagues. This substance, when administered intravenously or intranasally, elevates factor VIII levels transiently, and was found to be useful in treating minor bleeding episodes or in preventing postoperative hemorrhage when given prior to minor surgical operations in patients with mild to moderate hemophilia or some types of von Willebrand disease. Lusher introduced the
56:
20:
231:(IVIG) for the treatment of ITP in children, and reported its therapeutic effect in 1984. They also reported that IVIG could be an alternative to splenectomy in patients with the chronic form of childhood ITP. However, Lusher and colleagues also recognized that acute ITP in childhood was a self-limited condition, and did not necessarily require pharmacologic treatment.
167:, Ohio when she was three years old, and Lusher grew up there. Although her mother had French Canadian background and spoke French with her relatives, Lusher never learned French. During high school, she was interested in music, and played several instruments in the school band and orchestra, but later decided to pursue a career in science. Lusher never married.
183:(a rare occurrence for an X-linked recessive disorder), which stimulated her interest in blood coagulation and bleeding diseases. Her interest in bleeding disorders would later a become a lifelong dedication. In order to increase her knowledge in pediatric hematology, Lusher went to Children's Hospital of Michigan,
359:
Lusher served as the Marion I. Barnhart
Hemostasis Research Professor and Distinguished Professor of Pediatrics at Wayne State University; the director of the Hemophilia, Hemostasis and Thrombosis Program and the medical director of the coagulation laboratories at the Children's Hospital of Michigan.
262:
had been used since the 1970s as a bypassing agent in a few anecdotal cases of hemophilia with inhibitor development, but their efficacy had not been fully established. Lusher was able to demonstrate their efficacy in the treatment of joint bleeding in hemophilia in two multi-center studies in the
320:
treatment in patients with hemophilia (as opposed to on-demand treatment only during bleeding episodes) as she and other researchers had shown that this strategy drastically reduced complications such as joint damage after repeated bleeding episodes in patients with hemophilia. Lusher, along with
267:
in the treatment of bleeding episodes in patients with hemophilia. As this product was safer than prothrombin complex concentrates, and could be administered at home by the patients themselves, she and colleagues promoted its use in patients with inhibitors to treat bleeding episodes.
625:
Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate
Previously Untreated Patient Study Group. N Engl J Med
194:
At the completion her residency, Lusher returned to
Children's Hospital of Michigan, Detroit, for a fellowship in pediatric hematology/oncology (1964-1966). She completed the third year of her fellowship with Teresa Vietti at
226:
1- Immune
Thrombocytopenic Purpura: Lusher and Zuelzer presented a comprehensive description of the natural history of ITP in children as early as in 1966. Lusher and her colleague Indira Warrier were among the first to use
170:
Lusher received her medical degree from the
University of Cincinnati in 1960, and went on to do internship at the George Washington University Hospital in Washington D.C., and pediatric residency and chief residency at
241:
Lusher started the first comprehensive hemophilia program at the
Children's Hospital of Michigan in 1966. The available treatment for hemophilia at the time included transfusion of large volumes of fresh frozen
500:
Macik BG, Lindley CM, Lusher J, et al. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study. Blood Coagul
Fibrinolysis 1993;4:521-7.
615:
Lusher JM, Operskalski EA, Aledort LM, et al. Risk of human immunodeficiency virus type 1 infection among sexual and nonsexual household contacts of persons with congenital clotting disorders. Pediatrics
490:
Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med
481:
Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983;62:1135-8
536:
Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006;12 Suppl 6:54-61.
545:
Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von
Willebrands' diseases. Lancet 1977;1:869-72.
283:
use of desmopressin to the United States. After first trying it on herself and her colleagues, and documenting the rise of factor VIII levels, she proceeded to use it in patients with hemophilia and
527:
Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb
Haemost 1998;80:912-8.
254:
concentrates became available for the treatment of hemophilia A. One of the most frustrating complications in the treatment of hemophilia then, was the development of inhibitors to Factor VIII or
472:
Sonoda T, Solomon A, Krauss S, Cruz P, Jones FS, Levin J. Use of prothrombin complex concentrates in the treatment of a hemophilic patient with an inhibitor of factor VIII. Blood 1976;47:983-9.
445:
Lusher JM, Emami A, Ravindranath Y, Warrier AI. Idiopathic thrombocytopenic purpura in children. The case for management without corticosteroids. Am J Pediatr
Hematol Oncol 1984;6:149-57.
597:
Kaplan J, Sarnaik S, Gitlin J, Lusher J. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood 1984;64:308-10.
436:
Warrier IA, Lusher JM. Intravenous gammaglobulin (Gamimune) for treatment of chronic idiopathic thrombocytopenic purpura (ITP): a two-year follow-up. Am J Hematol 1986;23:323-8.
294:
In the 1980s, Lusher and her colleagues recognized an immune dysfunction in patients who received repeated blood transfusions, including patients with hemophilia. Specifically,
316:
became available, Lusher conducted one of the first clinical trials using these concentrates in the treatment of hemophilia patients, and showed its efficacy., Lusher promoted
791:
365:
509:
Lusher JM. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996;26 Suppl 1:124-30.
653:
Unuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia 2000;6:150-7.
398:
781:
771:
454:
Ravindranath Y. The American Society of Pediatric Hematology/Oncology Distinguished Career Award goes to Jeanne Lusher, M.D. J Pediatr Hematol Oncol 2002;24:169-71.
606:
Smith KJ, Lusher JM, Cohen AR, Salzman P. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Semin Hematol 1990;27:25-9.
191:, a prominent pediatric hematologist then. Upon her return to Charity Hospital, she took on the care of children with blood diseases and cancers there.
64:
786:
776:
564:
554:
Warrier AI, Lusher JM. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease. J Pediatr 1983;102:228-33.
220:
761:
427:
Warrier I, Lusher JM. Intravenous gamma globulin treatment for chronic idiopathic thrombocytopenic purpura in children. Am J Med 1984;76:193-8.
671:
Ewenstein BM, Takemoto C, Warrier I, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997;89:1115-6.
212:
662:
Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997;19:23-7.
302:
196:
39:
384:
146:
38:, and a researcher in the field of bleeding disorders of childhood, and has served as the director of Hemostasis Program at the
751:
259:
368:
Distinguished Career Award in 2002, and the Hemostasis & Thrombosis Research Society, Lifetime Achievement Award in 2009.
172:
127:
680:
DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007;138:305-15.
565:"ARMOUR's STIMATE (DESMOPRESSIN) APPROVED FOR HEMOPHILIA A :: "The Pink Sheet" :: Elsevier Business Intelligence"
99:
219:. For translational research, Lusher collaborated with Professor Marion I Barnhart from the physiology department of the
80:
766:
463:
Lusher JM. Development and introduction of recombinant factor VIII--a clinician's experience. Haemophilia 2012;18:483-6.
306:
288:
287:, and reported its efficacy. Desmopressin was finally approved for use in hemophilia and von Willebrand disease by the
344:
106:
69:
228:
73:
113:
644:
Lusher JM. Prophylaxis in children with hemophilia: is it the optimal treatment? Thromb Haemost 1997;78:726-9.
295:
264:
756:
284:
95:
199:, where she focused on pediatric oncology and the treatment protocols of the Southwest Oncology Group (
179:, Louisiana. During her pediatric residency at Charity Hospital, Lusher took care of a young girl with
699:
689:
Collins H. Early trial of gene therapy for hemophilia goes well. Pittsburgh Post-Gazette 2000 March 2.
305:(AIDS) in multi-transfused patients. The loss of countless patients with hemophilia to infection with
746:
635:
Haney DQ. Genetic engineers make clotting agent for hemophiliacs. The Daily Gazette 1990 December 27.
203:). Dr Lusher returned to Detroit in 1966, this time as a staff pediatric hematologist/oncologist.
585:
418:
Lusher JM, Zuelzer WW. Idiopathic thrombocytopenic purpura in childhood. J Pediatr 1966;68:971-9.
333:
361:
313:
322:
120:
280:
247:
188:
740:
348:
272:
243:
160:
31:
329:
317:
276:
251:
176:
30:, M.D. (June 9, 1935 - September 13, 2016) was an American physician, pediatric
364:
Physician of the Year Award by the National Hemophilia Foundation in 1993, the
83:. Contentious material about living people that is unsourced or poorly sourced
321:
other researchers, successfully used recombinant factor VIII concentrates for
298:
235:
216:
180:
164:
35:
337:
255:
19:
385:"Jeanne Marie Lusher M.D. Obituary - Visitation & Funeral Information"
328:
Lusher and colleagues reported on the peculiar side effect profile (i.e.,
184:
518:
Hedner U. History of rFVIIa therapy. Thromb Res 2010;125 Suppl 1:S4-6.
263:
early 1980s. Lusher later conducted the first studies on the use of
258:, which neutralized the activity of the factor given for treatment.
18:
200:
312:
Once the factor VIII concentrates that were manufactured using
49:
721:":: Hemostasis & Thrombosis Research Society ::"
720:
584:
Brody JE. "Dangers of little-known clotting disorders".
325:
induction in patients who had developed inhibitors.
366:American Society of Pediatric Hematology/Oncology
8:
343:Lusher also participated in a multi-center
246:to replenish the missing clotting factors.
792:Washington University in St. Louis fellows
700:"biography - Jeanne Lusher, MD (Michigan)"
221:Wayne State University School of Medicine
147:Learn how and when to remove this message
376:
42:until her retirement on June 28, 2013.
782:20th-century American women physicians
772:21st-century American women physicians
301:ratios were diminished, a hallmark of
401:. Prognosis.med.wayne.edu. 2013-07-05
7:
303:acquired immunodeficiency syndrome
159:Jeanne Lusher was born in 1935 in
14:
250:, and later in 1970, lyophilized
197:Washington University in St Louis
163:, Ohio, USA. Her family moved to
787:20th-century American physicians
777:21st-century American physicians
260:Prothrombin complex concentrates
211:Lusher's work focused mainly on
54:
762:University of Cincinnati alumni
340:in patients with hemophilia B.
213:Immune Thrombocytopenic Purpura
40:Children's Hospital of Michigan
1:
360:She was the recipient of the
187:for a brief rotation with Dr
567:. Elsevierbi.com. 1984-04-09
307:Human Immunodeficiency Virus
65:biography of a living person
271:The hemostatic efficacy of
85:must be removed immediately
808:
314:recombinant DNA technology
229:intravenous immunoglobulin
702:. Nlm.nih.gov. 2011-01-25
46:Early life and education
265:recombinant factor VIIa
752:American hematologists
285:von Willebrand disease
79:Please help by adding
24:
347:trial of Factor VIII
74:references or sources
22:
767:Women hematologists
588:, 1995 September 7.
28:Jeanne Marie Lusher
586:The Herald Journal
399:"Prognosis E-News"
334:nephrotic syndrome
63:This section of a
25:
16:American physician
362:Kenneth Brinkhous
336:) of recombinant
296:helper/suppressor
157:
156:
149:
131:
799:
732:
731:
729:
728:
717:
711:
710:
708:
707:
696:
690:
687:
681:
678:
672:
669:
663:
660:
654:
651:
645:
642:
636:
633:
627:
623:
617:
613:
607:
604:
598:
595:
589:
582:
576:
575:
573:
572:
561:
555:
552:
546:
543:
537:
534:
528:
525:
519:
516:
510:
507:
501:
498:
492:
488:
482:
479:
473:
470:
464:
461:
455:
452:
446:
443:
437:
434:
428:
425:
419:
416:
410:
409:
407:
406:
395:
389:
388:
381:
323:immune tolerance
173:Charity Hospital
152:
145:
141:
138:
132:
130:
89:
81:reliable sources
58:
57:
50:
807:
806:
802:
801:
800:
798:
797:
796:
737:
736:
735:
726:
724:
719:
718:
714:
705:
703:
698:
697:
693:
688:
684:
679:
675:
670:
666:
661:
657:
652:
648:
643:
639:
634:
630:
626:1993;328:453-9.
624:
620:
614:
610:
605:
601:
596:
592:
583:
579:
570:
568:
563:
562:
558:
553:
549:
544:
540:
535:
531:
526:
522:
517:
513:
508:
504:
499:
495:
491:1980;303:421-5.
489:
485:
480:
476:
471:
467:
462:
458:
453:
449:
444:
440:
435:
431:
426:
422:
417:
413:
404:
402:
397:
396:
392:
383:
382:
378:
374:
357:
275:, an analog of
248:Cryoprecipitate
209:
207:Research career
189:Wolf W. Zuelzer
153:
142:
136:
133:
96:"Jeanne Lusher"
90:
88:
78:
59:
55:
48:
17:
12:
11:
5:
805:
803:
795:
794:
789:
784:
779:
774:
769:
764:
759:
754:
749:
739:
738:
734:
733:
712:
691:
682:
673:
664:
655:
646:
637:
628:
618:
616:1991;88:242-9.
608:
599:
590:
577:
556:
547:
538:
529:
520:
511:
502:
493:
483:
474:
465:
456:
447:
438:
429:
420:
411:
390:
375:
373:
370:
356:
353:
208:
205:
155:
154:
62:
60:
53:
47:
44:
15:
13:
10:
9:
6:
4:
3:
2:
804:
793:
790:
788:
785:
783:
780:
778:
775:
773:
770:
768:
765:
763:
760:
758:
757:Living people
755:
753:
750:
748:
745:
744:
742:
722:
716:
713:
701:
695:
692:
686:
683:
677:
674:
668:
665:
659:
656:
650:
647:
641:
638:
632:
629:
622:
619:
612:
609:
603:
600:
594:
591:
587:
581:
578:
566:
560:
557:
551:
548:
542:
539:
533:
530:
524:
521:
515:
512:
506:
503:
497:
494:
487:
484:
478:
475:
469:
466:
460:
457:
451:
448:
442:
439:
433:
430:
424:
421:
415:
412:
400:
394:
391:
386:
380:
377:
371:
369:
367:
363:
354:
352:
350:
346:
341:
339:
335:
331:
326:
324:
319:
315:
310:
308:
304:
300:
297:
292:
290:
286:
282:
278:
274:
269:
266:
261:
257:
253:
249:
245:
239:
237:
232:
230:
224:
222:
218:
214:
206:
204:
202:
198:
192:
190:
186:
182:
178:
174:
168:
166:
162:
151:
148:
140:
137:December 2020
129:
126:
122:
119:
115:
112:
108:
105:
101:
98: –
97:
93:
92:Find sources:
86:
82:
76:
75:
71:
66:
61:
52:
51:
45:
43:
41:
37:
33:
29:
23:Jeanne Lusher
21:
725:. Retrieved
715:
704:. Retrieved
694:
685:
676:
667:
658:
649:
640:
631:
621:
611:
602:
593:
580:
569:. Retrieved
559:
550:
541:
532:
523:
514:
505:
496:
486:
477:
468:
459:
450:
441:
432:
423:
414:
403:. Retrieved
393:
379:
358:
349:gene therapy
342:
327:
318:prophylactic
311:
293:
273:desmopressin
270:
240:
233:
225:
210:
193:
169:
158:
143:
134:
124:
117:
110:
103:
91:
84:
67:
32:hematologist
27:
26:
747:1935 births
355:Recognition
330:anaphylaxis
277:vasopressin
252:factor VIII
177:New Orleans
741:Categories
727:2013-09-05
723:. Htrs.org
706:2013-09-05
571:2013-09-05
405:2013-09-05
372:References
299:lymphocyte
281:hemostatic
236:Hemophilia
217:hemophilia
215:(ITP) and
181:hemophilia
165:Cincinnati
107:newspapers
36:oncologist
338:factor IX
291:in 1984.
256:Factor IX
68:does not
345:phase 1
185:Detroit
121:scholar
70:include
244:plasma
161:Toledo
123:
116:
109:
102:
94:
128:JSTOR
114:books
201:SWOG
100:news
72:any
289:FDA
234:2-
175:in
743::
351:.
332:,
238::
223:.
730:.
709:.
574:.
408:.
387:.
150:)
144:(
139:)
135:(
125:·
118:·
111:·
104:·
87:.
77:.
34:/
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
